Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC + Ipilimumab in Advanced Melanoma
NCT01740297Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2013
- Primary completion
- Aug 2016
- Modality
- Oncolytic Viruses
- Countries
- 3
01
Overview
A Phase 2 trial of talimogene laherparepvec in melanoma, sponsored by Amgen. Started Feb 2013; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01740297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01740297.